Linked Life Data

15693640

Source:http://linkedlifedata.com/resource/pubmed/id/15693640

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2005-2-7
pubmed:abstractText
Anticholinergics are the bronchodilators of choice in the management of chronic obstructive pulmonary disease (COPD). They work by blocking muscarinic receptors in airway smooth muscle. Cholinergic tone appears to be the only reversible component of COPD. With the discovery of different muscarinic receptor subtypes, the development of more selective anticholinergics is possible. A major advance in this therapeutic area has been the discovery of tiotropium bromide, which has kinetic selectivity for M3 receptors as well as a duration of action of >24 hours. Once-daily administration of tiotropium is well tolerated and has shown significant advantages over ipratropium bromide, given 4 times daily, in the control of COPD.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0002-9343
pubmed:author
pubmed:issnType
Print
pubmed:day
20
pubmed:volume
117 Suppl 12A
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
24S-32S
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
The role of anticholinergics in chronic obstructive pulmonary disease.
pubmed:affiliation
Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom.
pubmed:publicationType
Journal Article, Review